MSD
Pembrolizumab/Lenvatinib
Biodrugs/ Drugs
Cancer
Lenvatinib in combination with Pembrolizumab in Participants with Metastatic Colorectal Cancer who have received and progressed on or after or became intolerant to prior treatment
3Phase III in Spain,
2Phase II,
1Phase I